Neuroprotective Effect of Thymoquinone, the Nigella Sativa Bioactive Compound, in 6-hydroxydopamine-induced Hemi-parkinsonian Rat Model

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2014 Apr 16

PMID 24734075

Citations 46

Authors

Reza Sedaghat

Mehrdad Roghani

Mohsen Khalili

Affiliations

Soon will be listed here.

Abstract

Parkinson disease (PD) is the most common movement disorder with progressive degeneration of midbrain dopaminergic neurons for which current treatments afford symptomatic relief with no-prevention of disease progression. Due to the neuroprotective property of the Nigella sativa bioactive compound thymoquinone (TQ), this study was undertaken to evaluate whether TQ could improve behavioral and cellular abnormalities and markers of oxidative stress in an experimental model of early PD in rat. Unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were daily pretreated p.o. with TQ at doses of 5 and/or 10 mg/Kg three times at an interval of 24 h. After 1 week, apomorphine caused contralateral rotations, a reduction in the number of neurons on the left side of the substantia nigra pars compacta (SNC) was observed, malondialdehyde (MDA) and nitrite level in midbrain homogenate increased and activity of superoxide dismutase (SOD) reduced in the 6-OHDA lesion group. TQ pretreatment significantly improved turning behavior, prevented loss of SNC neurons, and lowered level of MDA. These results suggest that TQ could afford neuroprotection against 6-OHDA neurotoxicity that is partly due to the attenuation of lipid peroxidation and this may provide benefits, along with other therapies, in neurodegenerative disorders including PD.

Citing Articles

6-shogaol against 3-Nitropropionic acid-induced Huntington's disease in rodents: Based on molecular docking/targeting pro-inflammatory cytokines/NF-κB-BDNF-Nrf2 pathway.

Jambi E, Alamri A, Afzal M, Al-Abbasi F, Al-Qahtani S, Almalki N PLoS One. 2024; 19(7):e0305358.

PMID: 39008492 PMC: 11249262. DOI: 10.1371/journal.pone.0305358.

Barbaloin's Chemical Intervention in Aluminum Chloride Induced Cognitive Deficits and Changes in Rats through Modulation of Oxidative Stress, Cytokines, and BDNF Expression.

Kazmi I, Afzal M, Imam F, Alzarea S, Patil S, Mhaiskar A ACS Omega. 2024; 9(6):6976-6985.

PMID: 38371830 PMC: 10870395. DOI: 10.1021/acsomega.3c08791.

Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease.

Ozsoy S, Cakir Z, Akcay E, Gevrek F Turk J Med Sci. 2023; 53(4):894-901.

PMID: 38031940 PMC: 10760553. DOI: 10.55730/1300-0144.5653.

Natural Phenolic Compounds with Neuroprotective Effects.

Tavan M, Hanachi P, de la Luz Cadiz-Gurrea M, Segura Carretero A, Mirjalili M Neurochem Res. 2023; 49(2):306-326.

PMID: 37940760 DOI: 10.1007/s11064-023-04046-z.

and its nano-mediated approach toward management of neurodegenerative disorders: A review.

Gawas C, Mathur S, Wani M, Tabassum H Ibrain. 2023; 9(1):111-123.

PMID: 37786518 PMC: 10529340. DOI: 10.1002/ibra.12091.

References

Zhou F, Wu J, Sun X, Yao H, Ding J, Hu G . Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology. 2007; 32(12):2570-80. DOI: 10.1038/sj.npp.1301381. View

Sriram K, OCallaghan J . Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol. 2007; 2(2):140-53. DOI: 10.1007/s11481-007-9070-6. View

Khan A, Vaibhav K, Javed H, Khan M, Tabassum R, Ahmed M . Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem. 2012; 369(1-2):55-65. DOI: 10.1007/s11010-012-1368-x. View

Radad K, Moldzio R, Taha M, Rausch W . Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phytother Res. 2008; 23(5):696-700. DOI: 10.1002/ptr.2708. View

Baluchnejadmojarad T, Roghani M . Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress. Behav Brain Res. 2011; 224(2):305-10. DOI: 10.1016/j.bbr.2011.06.007. View

Ruiz P, Catalan M, Fernandez Carril J . Initial motor symptoms of Parkinson disease. Neurologist. 2011; 17(6 Suppl 1):S18-20. DOI: 10.1097/NRL.0b013e31823966b4. View

Ullah I, Ullah N, Naseer M, Lee H, Kim M . Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons. BMC Neurosci. 2012; 13:11. PMC: 3317821. DOI: 10.1186/1471-2202-13-11. View

Roghani M, Niknam A, Jalali-Nadoushan M, Kiasalari Z, Khalili M, Baluchnejadmojarad T . Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull. 2010; 82(5-6):279-83. DOI: 10.1016/j.brainresbull.2010.06.004. View

Chen S, Le W . Neuroprotective therapy in Parkinson disease. Am J Ther. 2006; 13(5):445-57. DOI: 10.1097/01.mjt.0000174353.28012.a7. View

10.

Kanter M . Protective effects of thymoquinone on the neuronal injury in frontal cortex after chronic toluene exposure. J Mol Histol. 2010; 42(1):39-46. DOI: 10.1007/s10735-010-9305-3. View

11.

Chandra S, Mondal D, Agrawal K . HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. Exp Biol Med (Maywood). 2009; 234(4):442-53. DOI: 10.3181/0811-RM-317. View

12.

Oguz S, Kanter M, Erboga M, Erenoglu C . Protective effects of thymoquinone against cholestatic oxidative stress and hepatic damage after biliary obstruction in rats. J Mol Histol. 2012; 43(2):151-9. DOI: 10.1007/s10735-011-9390-y. View

13.

Ybot-Gorrin I, Vivancos-Matellano F, Chacon-Pena J, Alonso-Navarro H, Jimenez-Jimenez F . Assessment of Parkinson disease: what do we need to show neuroprotection?. Neurologist. 2011; 17(6 Suppl 1):S21-9. DOI: 10.1097/NRL.0b013e31823966c6. View

14.

Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B . Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry. 2007; 62(12):1353-62. DOI: 10.1016/j.biopsych.2007.04.020. View

15.

SHAPIRO R, Glick S, Camarota N . A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res. 1987; 426(2):323-31. DOI: 10.1016/0006-8993(87)90885-7. View

16.

Mu X, He G, Cheng Y, Li X, Xu B, Du G . Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav. 2009; 92(4):642-8. DOI: 10.1016/j.pbb.2009.03.008. View

17.

El Gazzar M, El Mezayen R, Marecki J, Nicolls M, Canastar A, Dreskin S . Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol. 2006; 6(7):1135-42. DOI: 10.1016/j.intimp.2006.02.004. View

18.

Schober A . Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004; 318(1):215-24. DOI: 10.1007/s00441-004-0938-y. View

19.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

20.

Eyhani-Rad S, Nayebi A, Mahmoudi J, Samini M, Babapour V . Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease. Iran J Pharm Res. 2013; 11(4):1175-81. PMC: 3813151. View